Onyx Bridge Wealth Group LLC Has $230,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Onyx Bridge Wealth Group LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 434 shares of the medical research company’s stock after selling 62 shares during the period. Onyx Bridge Wealth Group LLC’s holdings in Thermo Fisher Scientific were worth $230,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 104,536.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after purchasing an additional 8,347,260 shares during the period. Providence Capital Advisors LLC grew its position in shares of Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after buying an additional 5,832,730 shares during the last quarter. Norges Bank bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $3,105,677,000. Morgan Stanley lifted its stake in shares of Thermo Fisher Scientific by 17.7% in the fourth quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock worth $6,459,629,000 after acquiring an additional 1,764,312 shares during the period. Finally, International Assets Investment Management LLC increased its position in Thermo Fisher Scientific by 61,995.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock valued at $535,923,000 after purchasing an additional 1,008,045 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TMO. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. HSBC raised their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, The Goldman Sachs Group lifted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Stock Up 0.6 %

TMO stock traded up $3.26 during trading on Friday, reaching $544.78. The stock had a trading volume of 1,738,509 shares, compared to its average volume of 1,199,852. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company’s 50 day moving average is $571.27 and its two-hundred day moving average is $527.45. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $207.95 billion, a price-to-earnings ratio of 35.26, a P/E/G ratio of 2.28 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the company posted $5.40 earnings per share. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.